OmniChart

AMFW dazedandconfused 11 Nov 2015

Re: Where's Lambrini gone? Oh.. do stop it, girls!! Why would anyone post a Sell recommendation after a big fall? Unless they think it's going further down (which it still did after my buy back). But hopefully stabilised now and market will assess further..

SAB Afrosia 11 Nov 2015

Re: Job Done "...expected to complete in the second half of next year"That'll delay my new car purchase then.

SAB gamesinvestor 11 Nov 2015

Job Done [link] -- You can book that cruise now.Games

ARG NerveWreck 11 Nov 2015

In Auction This is so exciting.You could cut the tension with a tension-cutting device.

BRAM jezza51 11 Nov 2015

update Haven't had chance to look at update in any detail. Feels like 150 is reasonable target to buy. I didn't see this getting anywhere near this level - they remain well managed and will make the best of the new marketplace. Good job they raised money at 475! This market is merciless - good long term opportunity for the brave...

QPP Topalov 11 Nov 2015

Re: Edison Research I am always a bit sceptical of research commissioned by the company itself. A case in point being Cannacord's price target of around £6.50 for QPP which many on these boards quoted as their reason to buy.

QPP pendil 11 Nov 2015

Good news on SFO I always thought it would be misconceived for the SFO to target the Company, when, if fraud has been committed, the company of shareholders would have been the victim.Today the Telegraph reports:"The SFO has dropped its case against Olympus, two years after charging the company with making false and misleading financial statements.The regulator (sic) was forced to give up its prosecution after a court ruled that the misleading of auditors by a company was not an offence under English law....Only an individual can be prosecuted for the offence."SFO investigations may well continue but I would hope for an early confirmation that they are investigating individual directors not the company.This surely confirms that Court approval for the capital return will be granted. It had already been pitched at a level which I am sure they had been advised would (almost) certainly be approved.And just to confirm that no-one will have a capital gain unless their cost of acquisition is less than the sum of the capital distribution and the remaining value of their shares in Watchstone.

SAB Uncle Doug 11 Nov 2015

SAB selling Miller to Molson Coors 08:24 - News wires are starting to report that brewing giant SABMiller is to sell its Miller business in the US to Molson Coors as part of an agreed £68bn takeover by Budweiser-brewer Anheuser-Busch InBev.The reports follow an FT article, which says the sale is essential to help AB InBev win approval from US regulators for the deal.On the rise today ...

QPP oilovlam 11 Nov 2015

Re: Good news, bad news Even Tom WhiningFroth thinks it more likely that the SFO will go after RT & his ilk than the company and its shareholders. Of course that is only his opinion, which isn't worth anything really...less than nothing.I think OG/Tom have listened to the discussions on this board and understood some of what we write.Tom is a whining toad though. I don't know how people can put up with his verbal filth.

CRND rRomeo29 11 Nov 2015

Re: the next steps ahead ---------- -------"If no deal, so what?If we have a deal or don't have a deal, the money (more like time) needed to get this company profitable is the same. So why the gyrations from 25p to 6p? Its just opportunism.Hold your nerve and don't get suckered in to selling. Buying at this level is a steal!" polarityManSomeone seems to be rather confident omn lse-uk !

SKP Ambiorix1 11 Nov 2015

More on Exparel November 06, 2015 Pacira Pharmaceuticals announces positive data on the use of EXPAREL as a post surgical analgesic following total knee replacement surgery. The study, which compared the use of EXPAREL infiltration to the standard of care in 1,110 patients, found that EXPAREL was associated with significant improvements in a variety of patient and health economic outcomes, including Opioid use, hospital stay and readmission rate. The poster, titled Liposomal Bupivacaine versus Femoral Nerve Block for Post-operative Pain Control following Total Knee Arthroplasty, was presented at the annual meeting of the American Association of Hip and Knee Surgeons being held in Dallas on Nov. 6-8, 2015.In the study, patients who underwent total knee arthroplasty received identical pre-, intra- and postoperative pain management protocols, with the exception of 527 patients who received EXPAREL infiltration in place of a femoral nerve block. The poster's authors compared several patient and cost-related outcomes. Opioid use during hospitalization was significantly reduced in the EXPAREL group. Other key findings included shorter hospital length of stay, lower 30-day all-cause readmission rate, reduced inpatient fall rate and an increased rate of discharge to home."Based on analysis of incorporating liposomal bupivacaine into the postsurgical analgesic protocol following total knee arthroplasty has significant and quantifiable benefits to both the patient and the institution," said Richard Iorio, M.D., professor of orthopaedic surgery at NYU School of Medicine. "The measurable opioid-sparing effect of this new regimen has enabled us to virtually eliminate intravenous patient-controlled analgesia, or PCA, devices from the standard of care in total joint arthroplasty patients, without compromising patient comfort. In addition, we found that the incremental cost of adding this new modality was offset by meaningful savings from shorter anesthesia induction time in the operating room, shorter hospital stays and lower rates of 30-day readmission."(reworked article)Ambiorix

ETQ theprior 11 Nov 2015

SOLD !! To the highest bidder !345pShame, the company was beginning to make sense .....and they sell it !The buyer clearly knows a good thing when he sees it.Sad day for long term, long suffering shareholder !!TP

ETQ forwardloop 11 Nov 2015

co sold for only 345p Disappointing priceAt a PE of only 10 we were worth c 450pps

FENR Hardboy 11 Nov 2015

Finals We're still making a profit, and still covering the dividend; and with improved cash flow, so it's not total doom & gloom. The results put the PE under 10, which is cheap, but immediate growth looks unlikely, so it is probably a fair price.When they talk about the medium/long term there is still considerable optimism; but how long will their key sectors - mining, oil & gas - remain subdued. If China's demand is slowing it may be longer than we think. (It already has been longer than most folk expected.) The sour note came when they said the state of the US coal industry will lower this year's expectations, and that may push the price down a bit today; but overall it's much as expected, so there may not be much change. In fact the holding of the dividend may be seen as positive by the market. I'm a bit nervous with profits slipping and debt rising, and interest rates only going one way from here. Debt is beginning to look a little bit high for my liking.

MIRL zombynation 11 Nov 2015

News out on minera irl can anyone post the link